Grace Therapeutics, Inc. SEC filings GRCE

Grace Therapeutics, Inc. has 594 filings in SEC EDGAR's recent list, going back to Sep 2, 2008. Its latest annual report, Form 10-K, was filed on Jun 18, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on March 31.

Form Description Filed Period
DEFA14A Additional proxy material Jul 28, 2026 —
DEF 14A Proxy statement Jul 28, 2026 Sep 17, 2026
DEFA14A Additional proxy material Jul 28, 2025 —
DEF 14A Proxy statement Jul 28, 2025 Sep 12, 2025
DEFA14A Additional proxy material Sep 6, 2024 —
DEFA14A Additional proxy material Aug 7, 2024 —
DEFA14A Additional proxy material Aug 25, 2023 —
DEF 14A Proxy statement Aug 25, 2023 Oct 10, 2023
DEF 14A Proxy statement Aug 31, 2022 Sep 28, 2022
DEFA14A Additional proxy material Sep 11, 2020 —
DEF 14A Proxy statement Sep 9, 2020 Sep 30, 2020
PRE 14A Preliminary proxy statement Aug 7, 2020 Sep 30, 2020

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GRCE (Nasdaq)
Fiscal year ends
March 31
Incorporated in
DE
Headquarters
Princeton, NJ
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1444192
Former names
Acasti Pharma Inc. (until Oct 25, 2024)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.